Axonics says that its device significantly reduces the user's need to recharge as it marks its second clearance in only a ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 ...

Axonics announced today that it received regulatory approval in Australia for its R20 rechargeable sacral neuromodulation ...

Across medtech, companies have continued to innovate through the first nine months of 2024, and that rings especially true in ...

for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. IRVINE, Calif., April 30, 2024--Axonics, Inc. (Nasdaq ...

In May 2024, Axonics received regulatory approval from the TGA to market its F15® recharge-free SNM system. In Australia, Axonics also markets Bulkamid®, the company’s unique hydrogel ...

Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free ...

Axonics began commercial activities for its SNM systems in Australia in March 2023. By May 2024, it received TGA approval to market its F15 recharge-free SNM system. Axonics also offers Bulkamid ...

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel ...